var title_f36_55_37744="Vertebral anterior wedge fracture";
var content_f36_55_37744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior wedge fracture of the cervical spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37744=[""].join("\n");
var outline_f36_55_37744=null;
var title_f36_55_37745="Miliary lesions bartonellos";
var content_f36_55_37745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Miliary lesions (eruptive-phase bartonellosis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left foot of a 16-year-old patient from Peru showing numerous fine papular lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Maguina, C, Garcia, PJ, Gotuzzo, E, et al. Bartonellosis (Carrion's Disease) in the Modern Era. Clin Infect Dis 2001; 33:772. Copyright &copy;2001 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37745=[""].join("\n");
var outline_f36_55_37745=null;
var title_f36_55_37746="Tuberoeruptive xanthomata";
var content_f36_55_37746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberoeruptive xanthomata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tuberoeruptive xanthomata on the elbow and extensor surface of the arm in a patient with type III hyperlipoproteinemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington, P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37746=[""].join("\n");
var outline_f36_55_37746=null;
var title_f36_55_37747="Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Patient drug information";
var content_f36_55_37747=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/20/25924?source=see_link\">",
"     see \"Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5541091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Octaplex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702816",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to prothrombin complex, heparin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697906",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12048 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37747=[""].join("\n");
var outline_f36_55_37747=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5541091\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018119\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018118\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018123\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018124\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018126\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018121\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018122\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018127\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018128\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/20/25924?source=related_link\">",
"      Unactivated prothrombin complex concentrates (4 factors: II, VII, IX, and X with proteins C and S): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_55_37748="MRI T2 PMD";
var content_f36_55_37748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T2-weighted brain MRI of Pelizaeus-Merzbacher disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figures A and B demonstrate diffuse supratentorial high signal intensity throughout the deep and subcortical white matter. Figure C demonstrates infratentorial high signal in the cerebellar white matter, and some sparing of white matter in the brainstem.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Delilah M. Burrowes, MD, Children's Memorial Hospital, Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37748=[""].join("\n");
var outline_f36_55_37748=null;
var title_f36_55_37749="Photodynamic therapy of lung cancer";
var content_f36_55_37749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Photodynamic therapy of lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/55/37749/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37749/contributors\">",
"     Armin Ernst, MD, FCCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37749/contributors\">",
"     Joseph LoCicero, III, MD, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/55/37749/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37749/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/55/37749/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37749/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/55/37749/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the leading cause of cancer deaths in the United States for both women and men. Due to its association with tobacco use, many patients also suffer from impaired lung function due to chronic obstructive pulmonary disease (COPD). Consequently, surgical resection of some early stage tumors may be contraindicated because of concerns that reduced postoperative pulmonary function may necessitate chronic mechanical ventilation. Additionally, up to 10 percent of successfully resected patients with lung cancer subsequently develop a second primary lung neoplasm, and a second operation may not be feasible at that point. Thus, therapeutic approaches that spare functional lung tissue are required by many patients in whom lung cancer is diagnosed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6759?source=see_link\">",
"     \"Multiple primary lung cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-surgical treatments of lung cancer have grown more sophisticated over the past decade. The efficacy of systemic chemotherapy and both external and internal radiation (brachytherapy) have been demonstrated in numerous trials, and photodynamic therapy (PDT), endoscopic laser therapy, airway stenting, and cryotherapy are proven adjuncts for patients with endobronchial disease and obstructed central airways. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role and technical applications of PDT in the treatment of lung cancer will be reviewed here. Several studies have demonstrated the safety and effectiveness of this modality, and it is currently approved by the United States Food and Drug Administration (FDA) for the treatment of microinvasive endobronchial non-small cell lung cancer in patients for whom surgery and radiotherapy are not indicated, and for reducing obstruction and palliating symptoms in patients with completely or partially obstructing endobronchial non-small cell lung cancers. The technique may also be employed for the treatment of cancers of the esophagus, stomach, bladder, skin, and oropharynx, and it is undergoing evaluation for the treatment of central nervous system and biliary tree malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43881?source=see_link\">",
"     \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHOTOTOXIC REACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncologic treatment by drug-light interactions dates from 1903, when topical eosin and light were used to treat skin cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. With the emergence of injectable hematoporphyrin derivatives, photodynamic treatment of internal surface tumors became feasible in the 1970s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, the most commonly used agents are a mixture of different porphyrin-based oligomers, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39157?source=see_link\">",
"     porfimer",
"    </a>",
"    (Photofrin&reg;). A standard dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is injected intravenously slowly over 5 to 10 minutes. The drug is cleared from most organ systems within 72 hours, but is retained longer in tumors, skin (up to 30 days), liver, and spleen.",
"   </p>",
"   <p>",
"    Due to its preferential retention in tumor cells and in vascular endothelium, the cytotoxic reaction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39157?source=see_link\">",
"     porfimer",
"    </a>",
"    is somewhat selective for neoplastic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/5\">",
"     5",
"    </a>",
"    ]. After a set time interval (usually 48 hours), the tumor is exposed to light energy, which triggers the cytotoxic reaction. This reaction seems to be dependent primarily upon a type II photo-oxidative process, in which molecular oxygen is transformed to a cytotoxic singlet oxygen species in the presence of the light-excited sensitizer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. The neovascular endothelium of tumors seems particularly susceptible to PDT, with loss of capillary integrity soon after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIGHT SOURCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absorption peak for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39157?source=see_link\">",
"     porfimer",
"    </a>",
"    occurs at a wavelength of 405 nm. However, light of that wavelength is almost completely absorbed at the tissue surface and thus achieves only minimal and superficial tumor destruction. In order to achieve more penetration, a wavelength of 630 nm is used for therapeutic applications and results in tumor destruction to a depth of 5 to 10 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/7\">",
"     7",
"    </a>",
"    ]. The most commonly used light sources are argon-pumped or KTP (potassium-titanyl-phosphate)-pumped tunable dye lasers, which emit a nonthermal laser light.",
"   </p>",
"   <p>",
"    This light can be delivered through one of several types of fiber systems, which can be introduced via the working channel of a flexible bronchoscope. The most commonly used design is a cylindrical diffuser which differs from conventional laser fibers by emitting the light laterally in a 360 degree arc near its tip. The chosen tip length depends upon the length of the lesion.",
"   </p>",
"   <p>",
"    A microlens can be employed to focus light in a forward direction if required to treat small superficial tumors or a stump recurrence. The tip is also fairly rigid, permitting it to be embedded directly into a tumor if necessary (",
"    <a class=\"graphic graphic_picture graphicRef81291 \" href=\"mobipreview.htm?2/9/2206\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DOSIMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the laser light is nonthermal, the effects of PDT are not immediate. Total energy delivery depends upon the timing of treatment after injection of the sensitizing agent and the energy delivered through the fiber.",
"   </p>",
"   <p>",
"    Endoscopic introduction of the light source generally should be scheduled approximately 48 hours after injection. This allows for the sensitizer to wash out of normal mucosa, thus minimizing damage to nonmalignant tissue. It is recommended initially to apply 200 Joules per cm treated; additional energy may be applied during a follow-up bronchoscopy 2 days later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have presumed superficial carcinoma in-situ for which PDT is being considered, we suggest that endobronchial ultrasound (EBUS) be performed as a part of the initial work-up and staging. Assessment without EBUS frequently leads to underestimation of tumor extent and subsequent failure of endobronchial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the most part, PDT can be performed safely and conveniently with the flexible bronchoscope and moderate sedation. The use of a rigid bronchoscope should be reserved for the unstable or hypoxic patient but may also be indicated for prolonged procedures, when moderate sedation and topical anesthesia may not be sufficient.",
"   </p>",
"   <p>",
"    Application of 200 J generally requires 8 minutes with a KTP dye laser. If the lesion is longer than the chosen tip, the light fiber is repositioned to the non-treated area and an additional light application is administered.",
"   </p>",
"   <p>",
"    Adequate topical anesthesia is mandatory in order to eliminate coughing and inadvertent repositioning of the cylindrical diffuser. The nasal route is preferable, as the bronchoscope can more easily be held in a fixed position during light application. Once the tumor is visualized, the light fiber is introduced through the working channel of the bronchoscope; if possible, the rigid cylindrical tip should be embedded into the lesion. This not only protects healthy mucosa from light exposure, but also delivers more energy to the tumor itself.",
"   </p>",
"   <p>",
"    After suctioning all secretions, the bronchoscope is removed. A repeat bronchoscopy is planned in 48 hours, when the inflammatory response is particularly prominent and the resulting secretions can cause airway compromise. At that time all debris should be removed (",
"    <a class=\"graphic graphic_picture graphicRef54311 graphicRef57883 graphicRef68408 \" href=\"mobipreview.htm?7/37/7768\">",
"     picture 2A-C",
"    </a>",
"    ). Flexible bronchoscopy is usually sufficient for the repeat procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main adverse effect of PDT is photosensitivity of the skin. Immediate complications during the procedure are rare, since the light is non-thermal and no smoke or immediate tissue necrosis develops.",
"   </p>",
"   <p>",
"    Cough with some blood-streaked sputum is not uncommon after the procedure, and chest discomfort related to the inflammatory response may be noted. Within 24 to 48 hours after treatment, edema and secretions may lead to airway compromise. This is especially worrisome if the procedure was performed in the trachea or with higher energy levels. Respiratory compromise may also occur after treatment in more distal areas if lung function is marginal. Immediate therapeutic bronchoscopy must be available if retained secretions and debris are causing difficulties, and intubation and mechanical ventilation may be required.",
"   </p>",
"   <p>",
"    In an attempt to unify the reporting of problems and complications, a Photodynamic Therapy Side Effects and Symptoms Scale (PSES) was developed and validated. The PSES uses a ten point numeric scale to evaluate side effects, symptom trouble, or symptom burden on 13 items [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient teaching focuses on photosensitivity precautions. Patients will be photosensitive and at risk for sunburn immediately following the injection and for 4 to 6 weeks. Patients should use protective clothing and eyewear whenever exposed to bright sunlight. Sunscreen does NOT provide effective protection, since it does not filter all visible wavelengths. Shaded light, light from most artificial light sources, and from televisions does not generally pose problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PDT has the potential to cure early stage endobronchial lung tumors, as well as the ability to palliate central endobronchial obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. This was illustrated by an observational study of 175 patients who underwent PDT as treatment for endobronchial non-small cell lung cancer (NSCLC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/15\">",
"     15",
"    </a>",
"    ]. The five year disease-related survival rate was 93 percent among the patients with stage I disease, as defined by the 6th edition of the tumor node metastasis (TNM) staging system (",
"    <a class=\"graphic graphic_table graphicRef74820 \" href=\"mobipreview.htm?19/43/20157\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/17\">",
"     17",
"    </a>",
"    ]. Realize, this staging system has since been replaced by the 7",
"    <sup>",
"     th",
"    </sup>",
"    edition of the TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68104 \" href=\"mobipreview.htm?13/4/13388\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/18\">",
"     18",
"    </a>",
"    ]. The vast majority of patients with high-grade central airway stenoses were effectively palliated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung cancer-related deaths following PDT are more likely to be due to other primary lung cancers that were not recognized at the time of PDT (ie, metachronous multiple primary lung cancers) than the lesion on which PDT was performed. In an observational study of 48 patients who underwent PDT with curative intent, six deaths were due to metachronous or synchronous primary lung cancers, while only one death was due to the original malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/19\">",
"     19",
"    </a>",
"    ]. PDT may be an effective approach to managing metachronous and synchronous primary lung cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/20\">",
"     20",
"    </a>",
"    ]. Metachronous and synchronous lesions are defined elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6759?source=see_link&amp;anchor=H2#H2\">",
"     \"Multiple primary lung cancers\", section on 'Definitions'",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    PDT has also been used with success to treat superficial shallow lesions, stump recurrence, distal endobronchial obstruction, endobronchial metastases of nonpulmonary malignancies, and hemoptysis from an endobronchial arteriovenous malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/11,21,22\">",
"     11,21,22",
"    </a>",
"    ]. It is also an effective technique for patients with a low performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of peripheral lung cancer with PDT has been less successful. This was illustrated by an uncontrolled trial of nine patients who underwent computed tomography (CT)-guided PDT for treatment of peripheral lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/24\">",
"     24",
"    </a>",
"    ]. Only a partial response was achieved in seven patients. These results suggest that differences in the location of the tumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the technique used to administer PDT may affect the outcome.",
"   </p>",
"   <p>",
"    The efficacies of PDT and Nd:YAG laser therapy for the palliation of symptoms caused by endobronchial obstruction appear to be similar, according to a randomized trial that directly compared the modalities in patients with inoperable NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/25\">",
"     25",
"    </a>",
"    ]. Given the comparable efficacy, we generally prefer PDT to Nd:YAG laser therapy because PDT does not generate endobronchial smoke and can be performed in an oxygen-rich environment. In addition, the risk for acute bronchial perforation appears to be less and the effects may be longer lasting with PDT.",
"   </p>",
"   <p>",
"    PDT has been successfully combined with other endobronchial therapies, including brachytherapy and laser therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37749/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=see_link\">",
"     \"Endobronchial brachytherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In experienced hands, photodynamic therapy (PDT) provides a safe, alternative therapy for malignant airway obstruction and also offers the possibility of curing early stage non-small cell lung cancer. PDT should complement, rather than replace, other treatment modalities whenever possible. New photosensitizers with more specificity for cancerous tissue and thus less associated photosensitivity are under development and may further improve the safety and efficacy of the procedure.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/1\">",
"      Von Tappeiner, H, Jesionek, A. Therapeutische versuche mit floureszierenden stoffen. Muench Med Wschrf 1903; 47:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/2\">",
"      Von Tappeiner, H, Jodlbauer, A. Ueber die wirkung der photodynamischen (floureszierenden) stoffe auf protozoen und enzyme. Dtsch Arch Klin Med 1904; 80:427.",
"     </a>",
"    </li>",
"    <li>",
"     Dougherty T, Boyle DG, et al. Phototherapy of human tumors. In: Research in Photobiology, Castellani A (Ed), Plenum, New York, NY 1977. p.435-466.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/4\">",
"      Dougherty TJ. Hematoporphyrin derivative for detection and treatment of cancer. J Surg Oncol 1980; 15:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/5\">",
"      Gomer CJ, Dougherty TJ. Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res 1979; 39:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/6\">",
"      Edell ES, Cortese DA. Photodynamic therapy. Its use in the management of bronchogenic carcinoma. Clin Chest Med 1995; 16:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/7\">",
"      Dougherty TJ, Marcus SL. Photodynamic therapy. Eur J Cancer 1992; 28A:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/8\">",
"      Miyazu Y, Miyazawa T, Kurimoto N, et al. Endobronchial ultrasonography in the assessment of centrally located early-stage lung cancer before photodynamic therapy. Am J Respir Crit Care Med 2002; 165:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/9\">",
"      Goodell T. Measuring subjective side effects and symptoms in palliative photodynamic therapy. Oncol Nurs Forum 2006; 33:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/10\">",
"      Moghissi K. Role of bronchoscopic photodynamic therapy in lung cancer management. Curr Opin Pulm Med 2004; 10:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/11\">",
"      McCaughan JS Jr. Photodynamic therapy of endobronchial and esophageal tumors: an overview. J Clin Laser Med Surg 1996; 14:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/12\">",
"      Kato H, Okunaka T, Shimatani H. Photodynamic therapy for early stage bronchogenic carcinoma. J Clin Laser Med Surg 1996; 14:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/13\">",
"      Cortese DA, Edell ES, Kinsey JH. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 1997; 72:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/14\">",
"      Moghissi K, Dixon K, Stringer M, et al. The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases. Eur J Cardiothorac Surg 1999; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/15\">",
"      McCaughan JS Jr, Williams TE. Photodynamic therapy for endobronchial malignant disease: a prospective fourteen-year study. J Thorac Cardiovasc Surg 1997; 114:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/16\">",
"      Maziak DE, Markman BR, MacKay JA, et al. Photodynamic therapy in nonsmall cell lung cancer: a systematic review. Ann Thorac Surg 2004; 77:1484.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC Cancer Staging Manual, 6th ed, Greene FL, Page DL, Fleming ID, et al (Eds), Springer, New York 2002.",
"    </li>",
"    <li>",
"     Lung. In: AJCC Cancer Staging Manual, 7th, Edge SB, Byrd DR, Carducci M, Compton CC, Fritz AG (Eds), Springer, New York 2009..",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/19\">",
"      Endo C, Miyamoto A, Sakurada A, et al. Results of long-term follow-up of photodynamic therapy for roentgenographically occult bronchogenic squamous cell carcinoma. Chest 2009; 136:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/20\">",
"      Usuda J, Ichinose S, Ishizumi T, et al. Management of multiple primary lung cancer in patients with centrally located early cancer lesions. J Thorac Oncol 2010; 5:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/21\">",
"      McCaughan JS Jr. Survival after photodynamic therapy to non-pulmonary metastatic endobronchial tumors. Lasers Surg Med 1999; 24:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/22\">",
"      McCaughan JS Jr, Hawley PC, LaRosa JC, et al. Photodynamic therapy to control life-threatening hemorrhage from hereditary hemorrhagic telangiectasia. Lasers Surg Med 1996; 19:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/23\">",
"      Hugh-Jones P, Gardner WN. Laser photodynamic therapy for inoperable bronchogenic squamous carcinoma. Q J Med 1987; 64:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/24\">",
"      Okunaka T, Kato H, Tsutsui H, et al. Photodynamic therapy for peripheral lung cancer. Lung Cancer 2004; 43:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/25\">",
"      Diaz-Jim&eacute;nez JP, Mart&iacute;nez-Ballar&iacute;n JE, Llunell A, et al. Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction. Eur Respir J 1999; 14:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/26\">",
"      Freitag L, Ernst A, Thomas M, et al. Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma. Thorax 2004; 59:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37749/abstract/27\">",
"      Santos RS, Raftopoulos Y, Keenan RJ, et al. Bronchoscopic palliation of primary lung cancer: single or multimodality therapy? Surg Endosc 2004; 18:931.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4382 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37749=[""].join("\n");
var outline_f36_55_37749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHOTOTOXIC REACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIGHT SOURCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DOSIMETRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4382\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4382|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/9/2206\" title=\"picture 1\">",
"      Flexible cylindrical diffuser",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/19/13616\" title=\"picture 2A\">",
"      Endobronchial lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/1/10256\" title=\"picture 2B\">",
"      Delivery of PDT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/15/44272\" title=\"picture 2C\">",
"      Results of photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4382|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/43/20157\" title=\"table 1\">",
"      Lung cancer TMN staging 6th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/41/37533\" title=\"table 2\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/4/13388\" title=\"table 3\">",
"      Changes 7th ed TNM lung ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37033?source=related_link\">",
"      Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=related_link\">",
"      Endobronchial brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=related_link\">",
"      Endoscopic palliation of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43881?source=related_link\">",
"      Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6759?source=related_link\">",
"      Multiple primary lung cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_55_37750="EPA DPA DHA chemicals";
var content_f36_55_37750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Structure of long-chain n-3 PUFA found in fish oil",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 469px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-chain n-3 PUFA are almost exclusively derived from seafood sources and include eicosapentaenoic acid (EPA,20:5n-3), docosapentaenoic acid (DPA,22:5n-3), and docosahexaenoic acid (DHA,22:6n-3). Given the long carbon chains and multiple double bonds, these fatty acids have complex 3-dimensional configurations, very different from the relatively straight chains of most other fatty acids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37750=[""].join("\n");
var outline_f36_55_37750=null;
var title_f36_55_37751="ECG of sinus rhythm";
var content_f36_55_37751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal sinus rhythm at a rate of 71 beats/min, a P wave axis of 45&deg;, and a PR interval of 0.15 sec.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37751=[""].join("\n");
var outline_f36_55_37751=null;
var title_f36_55_37752="Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients";
var content_f36_55_37752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/55/37752/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37752/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/55/37752/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37752/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/55/37752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37752/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/55/37752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic kidney disease are commonly iron deficient. Adequate iron stores are essential for achieving maximum benefit from erythropoietic-stimulating agents (ESAs), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (EPO) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    . Decreased iron stores or decreased availability of iron are the most common reasons for resistance to the effect of these agents.",
"   </p>",
"   <p>",
"    An overview of the use of iron in non-dialysis, peritoneal dialysis, and home hemodialysis patients is presented in this topic review. Discussions related to the use of iron in hemodialysis patients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF IRON DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating therapy, iron stores must be assessed and non-renal causes of anemia excluded. As discussed in detail separately, the evaluation of patients with kidney disease and anemia includes red blood cell indices, reticulocyte count, serum iron, total iron binding capacity, percent transferrin saturation, serum ferritin, and when appropriate, testing for occult blood in stool. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Absolute and functional iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important issue in the diagnosis of iron deficiency in the patient with chronic kidney disease (CKD) or end-stage renal disease is that the laboratory criteria are markedly different from those in patients with relatively normal renal function.",
"   </p>",
"   <p>",
"    Absolute iron deficiency as determined by assessment of bone marrow iron stores is likely to be present in patients with CKD when [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The percent transferrin saturation (TSAT) (plasma iron divided by total iron binding capacity x 100) falls below 20 percent.",
"     </li>",
"     <li>",
"      The serum ferritin concentration is less than 100",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the TSAT and serum transferrin are above these levels, most patients will have normal amounts of bone marrow iron. However, many patients with TSAT and serum ferritin above these levels will still respond to supplemental intravenous iron administration with an increase in hemoglobin level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction in ESA dose. Thus neither the TSAT nor serum ferritin predict with accuracy which patients will have an improved response to ESAs after iron supplementation, except that the likelihood of a response is small in patients whose levels reach approximately 30 percent and 500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    In addition to absolute iron deficiency, it is now recognized that dialysis patients may have functional iron deficiency. This is characterized by the presence of adequate iron stores, as defined by conventional criteria, but an inability to sufficiently mobilize this iron when erythropoiesis is stimulated by an erythropoietic stimulating agent. Functional deficiency is associated with transferrin saturation &le;20 percent and elevated ferritin levels (between approximately 100 to 800",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or even higher). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28005?source=see_link\">",
"     \"Diagnosis of iron deficiency in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR IRON THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initiation of iron therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiation of treatment with an ESA, we recommend the administration of iron therapy among non-dialysis, peritoneal dialysis, and home hemodialysis patients who have evidence of absolute iron deficiency (ie, TSAT less than 20 percent and a serum ferritin concentration less than 100",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    In addition, we suggest the administration of iron among patients who have a TSAT &le;30 percent and ferritin &le;500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    providing an underlying infection has been excluded and there is reason to increase the Hgb level. This is principally because ESA therapy requires significant amounts of supplemental iron for effective erythropoiesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iron therapy and ESA are administered to achieve target hemoglobin levels between 10 and 11.5",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Thus, these agents are indicated in patients with anemia due to CKD and hemoglobin levels less than 10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Repletion of iron stores alone will raise the hemoglobin level to the target level in a significant proportion of patients.",
"   </p>",
"   <p>",
"    <br/>",
"    A sufficient amount of iron should be administered to correct the iron deficiency. In this setting, we aim to increase hemoglobin levels, raise the transferrin saturation up to 30 percent, and increase the ferritin level up to 500",
"    <span class=\"nowrap\">",
"     mg/mL.",
"    </span>",
"    We do not routinely administer iron to patients with ferritin levels above 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and anemia, although each patient should be individually assessed.",
"   </p>",
"   <p>",
"    There are no randomized controlled trials that have compared different iron target levels among non-dialysis and peritoneal dialysis patients. Support for the specific iron target levels discussed in this topic review is therefore derived almost entirely from data among in-center hemodialysis patients. However, evidence from in-center hemodialysis patients may not directly apply to non-dialysis and peritoneal dialysis patients, since dialysis-related blood loss does not occur. The studies that have examined these issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2012 KDIGO guidelines suggest oral or intravenous iron therapy for patients with a transferrin saturation &le;30 percent and ferritin &le;500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for oral versus intravenous iron therapy are discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Indications for oral versus intravenous iron therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Maintenance iron therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;To ensure an adequate response with erythropoietic agents, most patients will also require supplemental iron on a continuing basis in order to prevent absolute iron deficiency. In addition, we agree with the 2012 KDIGO guidelines, which recommend iron therapy during administration of erythropoietin stimulating agents (ESAs) if the following conditions are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increase in Hb concentration or a decrease in ESA dose is desired.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transferrin saturation &le;30 percent and ferritin &le; 500",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some recommend caution in administering intravenous iron among patients with possibly excessive iron stores, which are suggested by a serum ferritin concentration above 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a transferrin saturation above 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Although there is little objective evidence that continued iron therapy in such patients results in iron toxicity, it is not likely to significantly enhance erythropoiesis.",
"   </p>",
"   <p>",
"    At present, we do not routinely recommend administration of intravenous iron to patients with ferritin levels above 500",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    and anemia, although each patient should be individually assessed. An initial trial of increased EPO dose alone, without intravenous iron, may also be reasonable if the hemoglobin level is persistently below 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    with an ESA dose that is not particularly high. The long-term clinical benefit and safety of providing additional supplemental iron in the setting of anemia with persistently elevated ferritin levels remains to be determined.",
"   </p>",
"   <p>",
"    This view is consistent with the 2012 KDIGO guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/2\">",
"     2",
"    </a>",
"    ]. The Work Group recommends, in the patient with a serum ferritin concentration above 500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    that a decision concerning iron administration should be based upon considerations of the patient's clinical status, hemoglobin and TSAT, and erythropoietic agent responsiveness as well as subsequent trends in these laboratory measures.",
"   </p>",
"   <p>",
"    Indications for oral versus intravenous iron therapy are discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Indications for oral versus intravenous iron therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORAL VERSUS INTRAVENOUS IRON THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron may be given orally or intravenously to treat and prevent development of iron deficiency. We suggest a trial of oral iron for non-dialysis patients who are selected for iron therapy. We suggest intravenous iron for peritoneal dialysis and hemodialysis patients who are prescribed such therapy.",
"   </p>",
"   <p>",
"    The rationale for using oral iron among non-dialysis CKD patients is that it is inexpensive, readily available and does not require IV access.",
"   </p>",
"   <p>",
"    There have been several randomized prospective studies that have compared parenteral and oral iron therapy in non-dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. These studies have reported inconsistent findings concerning the relative efficacy of oral iron and intravenous iron therapy.",
"   </p>",
"   <p>",
"    As an example, a Cochrane meta-analysis showed an increase in hemoglobin concentration (8 studies, 1020 patients), ferritin concentration (7 studies, 771 patients), and transferrin saturation (6 studies, 729 patients) associated with intravenous compared with oral iron among non-dialysis CKD patients, however the effect was small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/10\">",
"     10",
"    </a>",
"    ]. The consensus of the 2012 KDIGO work group was that, for non-dialysis CKD patients, a clearly defined benefit of intravenous iron therapy was not supported by evidence at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/2\">",
"     2",
"    </a>",
"    ]. The 2012 KDIGO guidelines have recommended that either oral iron therapy or intravenous iron therapy can be given in non-dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of oral iron among non-dialysis CKD patients may be limited by gastrointestinal side effects: for such patients who do not tolerate oral iron, we recommend intravenous iron therapy.",
"   </p>",
"   <p>",
"    Iron indices should be re-evaluated after one to two months of therapy. If the transferrin saturation remains below 30 percent, the hemoglobin level does not increase to the target level, and the serum ferritin level remains below 500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    we recommend parenteral iron therapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Indications for iron therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Intravenous iron is preferred rather than oral iron in most patients on peritoneal dialysis and home hemodialysis since oral iron is unlikely to have a significant erythropoietic benefit.",
"   </p>",
"   <p>",
"    The relative efficacy and safety of intravenous iron versus oral iron in patients on peritoneal dialysis has been evaluated in a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. As an example, one randomized prospective study of 46 peritoneal dialysis patients found that intravenous iron (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    ) was significantly more effective than oral iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/13\">",
"     13",
"    </a>",
"    ]. Several other studies also support the concept that intravenous iron is more effective than oral iron and that oral iron may in fact be relatively poorly absorbed and hence ineffective in these patients.",
"   </p>",
"   <p>",
"    The 2012 KDIGO guidelines suggest IV iron for peritoneal dialysis patients on ESA therapy who meet the criteria listed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Maintenance iron therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Limited studies have compared oral and intravenous iron therapy among home hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/11\">",
"     11",
"    </a>",
"    ]. However, as with in-center hemodialysis patients, home hemodialysis patients can have significant ongoing blood losses. Thus, despite the absence of studies in these patients, the findings among in-center hemodialysis patients that oral iron is significantly less effective than intravenous iron is likely to apply in home hemodialysis patients. These studies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2012 KDIGO guidelines suggest IV iron for hemodialysis patients on ESA therapy who meet the criteria listed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Maintenance iron therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Limited evidence suggests that supraphysiologic dosing of oral iron may be effective in some settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In a prospective study, the oral administration of one large dose of iron sulfate (260 mg elemental iron) among fasting subjects significantly increased serum iron concentrations in both peritoneal dialysis patients and normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/17\">",
"     17",
"    </a>",
"    ]. Although the dose was well tolerated and apparently effective, it is unclear if similar benefits can be obtained with chronic dosing or if such an approach enhances erythropoiesis is a meaningful way on a chronic basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ORAL IRON FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who are selected for oral iron therapy, we suggest that iron be administered at a daily dose of at least 200 mg of elemental iron. Because of simplicity and cost issues, we suggest giving this as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    325 mg (65 mg elemental iron per tablet) three times daily. Intestinal iron absorption may be normal or impaired in patients with renal failure, and may be reduced by food and antacids. Thus, oral iron should be given between meals, if tolerated. Giving one of the doses at bedtime may be a simple and effective expedient. Other iron preparations are also available but tend to be more expensive without greater efficacy or consistently fewer side effects.",
"   </p>",
"   <p>",
"    Intestinal iron absorption is intrinsically normal in renal failure, but may be reduced by food and antacids. Thus, oral iron should be given between meals, if tolerated. Giving one of the doses at bedtime may be a simple and effective expedient.",
"   </p>",
"   <p>",
"    Because of the decreased efficacy and other adverse factors associated with traditional oral iron, a new generation of oral iron products has been developed. For example, heme iron polypeptide is absorbed in the gastrointestinal tract via different mechanisms from nonheme iron, resulting in absorption kinetics and side effects that differ from traditional iron products. In a six-month prospective trial of hemodialysis patients, heme iron polypeptide adequately maintained both hemoglobin levels and serum iron indices after substituting for intravenous iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/19\">",
"     19",
"    </a>",
"    ]. Although further study is needed, these results suggest that this oral formulation may become a viable option for iron delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PARENTERAL IRON PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, we prefer initiating iron therapy with intravenous iron in most peritoneal dialysis and home hemodialysis patients. Intravenous iron should also be used in non-dialysis CKD patients if oral iron is not able to maintain the transferrin saturation above 30 percent (and the serum ferritin &le;500",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    for patients in whom the target hemoglobin level cannot be maintained with modest doses ESAs.",
"   </p>",
"   <p>",
"    Due to their superior safety profiles, we recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    in sucrose complex,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    for treatment of iron deficiency in non-dialysis, peritoneal dialysis, and home hemodialysis patients.",
"   </p>",
"   <p>",
"    As with in-center hemodialysis patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    in sucrose complex are intravenous options in non-dialysis, peritoneal dialysis, and home hemodialysis patients. A general discussion of the efficacy and safety related to these preparations is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of iron preparations in hemodialysis patients\", section on 'Parenteral iron preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to in-center hemodialysis patients, peritoneal dialysis patients and non-dialysis patients do not have ready intravenous access three times weekly for the administration of intravenous iron. As a result, attention has focused upon the efficacy and safety of delivering relatively larger doses of iron at more infrequent intervals than that normally administered to in-center hemodialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Iron dextran",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of the non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    iron preparations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    was the only preparation available for intravenous administration. If the test dose of iron dextran was tolerated, 500 to 1000 mg of iron dextran could be administered intravenously in a single infusion to replenish iron stores; this dose could then subsequently be repeated as required.",
"   </p>",
"   <p>",
"    A significant number of prospective studies have found that this dose is effective and relatively well tolerated, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    is associated with a significant risk of anaphylaxis. The following is a survey of some of the studies that examined the efficacy of this agent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective open-label study evaluated the effectiveness of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      in 20 chronic peritoneal or home hemodialysis patients, with iron deficiency defined as ferritin &lt;100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an iron saturation &le;20 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/11\">",
"       11",
"      </a>",
"      ]. A median iron dose of 1000 mg resulted in an increase in hematocrit (29 to 31 percent), iron saturation (13 to 22 percent) and ferritin levels (234 to 305",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"      The infusion was well tolerated.",
"     </li>",
"     <li>",
"      A retrospective study compared the efficacy and safety of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      and iron saccharate among 61 peritoneal dialysis patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/12\">",
"       12",
"      </a>",
"      ]. Thirty-three patients received iron",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      , 23 received iron saccharate, and five received both iron dextran and iron saccharate. At three months, there was an increase in hemoglobin level (98 to 110",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      ferritin (105 to 392",
"      <span class=\"nowrap\">",
"       microg/L),",
"      </span>",
"      and transferrin saturation (17 to 26 percent). Side effects were more common with iron dextran.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As described in detail separately,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    is associated with a significantly higher incidence of serious adverse effects, particularly anaphylaxis, than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    in sucrose complex, and some iron",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    preparations appear to be associated with a higher frequency of adverse events than others. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Iron sucrose and ferric gluconate in sucrose complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    in sucrose complex in doses larger than the normal doses of 100 and 125 mg, respectively, has been evaluated. In most patients, doses of iron sucrose up to 300 mg given over two hours and 400 mg over 2.5 hours seem to be well tolerated by most patients. In addition, ferric gluconate in sucrose complex has been well tolerated in most patients at doses of up to 250 mg that are administered over one to two hours. There have been no studies that have directly compared the efficacy and safety of these agents in this setting.",
"   </p>",
"   <p>",
"    The following are some of the studies in support of the use of these higher doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/20-26\">",
"     20-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective study evaluated a total of 335 iron infusions of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      administered to 249 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/20\">",
"       20",
"      </a>",
"      ]. These were given in 200, 300, 400, or 500 mg infusions over two hours. Both the 200 and 300 mg doses of intravenous iron sucrose administered over two hours were tolerated and appeared to be safe. By comparison, a high incidence of adverse events with the 400 and 500 mg doses administered as a two hour infusion was noted.",
"     </li>",
"     <li>",
"      In a retrospective study of 40 patients with chronic renal failure, 79 treatments of 250 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      infused over one to four hours reported that four treatments were associated with side effects, which included diarrhea, vomiting, low back pain, hypotension, and burning sensation in feet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/24\">",
"       24",
"      </a>",
"      ]. The duration of infusion did not appear to influence the side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the incidence of side effects is not extremely high, caution must be exercised when administering any preparation of intravenous iron, particularly with doses higher than those typically used in in-center hemodialysis patients. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study compared the efficacy and safety of two large doses of intravenous iron (500 mg each administered one week apart) given as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      (iron saccharate), or both preparations to 33, 23, and 5 iron deficient peritoneal dialysis patients, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/12\">",
"       12",
"      </a>",
"      ]. Both iron preparations were equally effective in restoring iron balance. Five patients given iron",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      developed minor side effects, and one had anaphylaxis. By comparison, two patients receiving iron sucrose had transient chest pain and one experienced an anaphylactic reaction.",
"     </li>",
"     <li>",
"      In an analysis of over 2000 injections administered to 533 patients with CKD not on dialysis and 124 patients on peritoneal dialysis, 200 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      administered as a bolus injection over two minutes was well tolerated in 97.5 percent of injections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/27\">",
"       27",
"      </a>",
"      ]. There were seven anaphylactoid reactions, all of which resolved within 30 minutes, and 40 instances of pain during or after the injection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common side effects are hypotension, nausea, vomiting, and abdominal discomfort; these effects are generally self-limited and do not require intervention other than perhaps slowing the rate of iron infusion. In addition, evidence that parenteral iron induces renal tubular injury in non-dialysis patients has been reported, although an effect on glomerular filtration rate was not demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal regimens for either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    in sucrose complex and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    are unclear. At present, we administer these agents in the following regimens:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      300 to 400 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      can be administered once every week (or less often if necessary, ie for patient convenience, etc.) for two to three doses to provide a total dose of 600 to 1000 mg, as needed. If these doses are not well tolerated, additional doses of 200 mg can often be used.",
"     </li>",
"     <li>",
"      250 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      in sucrose complex can be administered once weekly (or less often if necessary, ie for patient convenience, etc.) for three to four doses, as needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In peritoneal dialysis patients and home hemodialysis patients, another option is the quarterly intravenous administration of 300 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    or 250 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    in sucrose complex. This dosing can provide maintenance iron therapy and prevent the development of iron deficiency. For peritoneal dialysis patients, a 2005 revision to the iron sucrose package insert suggests an alternative dosing regimen. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     \"Iron sucrose: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some home hemodialysis programs, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    (Venofer) is self-administered by patients at home. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3465?source=see_link&amp;anchor=H16#H16\">",
"     \"Outcomes associated with nocturnal hemodialysis\", section on 'Erythropoietin and iron administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443966\">",
"    <span class=\"h2\">",
"     Ferumoxytol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new parenteral iron preparation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    (Feraheme), has been approved by the FDA in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444088\">",
"    <span class=\"h3\">",
"     Efficacy and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     Ferumoxytol",
"    </a>",
"    appears to be safe and effective when given as a rapid infusion of up to 510 mg in patients with CKD and patients on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Among 230 hemodialysis patients, for example, one randomized study evaluated the increase in hemoglobin and safety among those who received either two injections of 510 mg of ferumoxytol administered within seven days of each other or oral iron (200 mg per day) administered for a total of 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/32\">",
"     32",
"    </a>",
"    ]. An increase in hemoglobin levels was significantly more common with ferumoxytol (1 versus 0.46",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"    Both arms had similar adverse event rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444153\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the prescribing information monograph, 510 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    can be administered intravenously at a rapid rate (up to 30",
"    <span class=\"nowrap\">",
"     mg/sec)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/33\">",
"     33",
"    </a>",
"    ]. For the treatment of iron deficiency in those with CKD, the manufacturer recommends an initial 510 mg dose to be followed by a second 510 mg injection three to eight days after the first dose. A decision to administer a second dose should be based on consideration of severity of iron deficiency, hemoglobin level, and ESA responsiveness.",
"   </p>",
"   <p>",
"    In the absence of direct comparisons of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    and other intravenous iron preparations, the assessment of relative safety and efficacy is not possible. The ability to provide large iron doses with short administration times is potentially attractive for hemodialysis patients as well as patients on peritoneal dialysis and CKD patients being administered ESA therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other parenteral iron preparations are available outside the United States. In a European study, single ferric carboxymaltose (Injectafer) injections or infusions were well tolerated in patients with non-dialysis chronic kidney disease and kidney transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37752/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional iron preparations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with chronic kidney disease (CKD) are commonly iron deficient. Prior to initiating iron therapy, iron stores must be assessed and non-renal causes of anemia excluded. As discussed in detail separately, the evaluation of patients with kidney disease and anemia must include red blood cell indices, reticulocyte count, serum iron, total iron binding capacity, percent transferrin saturation (TSAT), serum ferritin, and testing for blood in stool. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis of iron deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with CKD, absolute iron deficiency is likely to be present when the TSAT is &le;20 percent and the serum ferritin concentration &le;100",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Absolute and functional iron deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional iron deficiency is characterized by the presence of adequate iron stores, but the relative inability to sufficiently mobilize this iron when erythropoiesis is stimulated by an erythropoietic stimulating agent (ESA). Functional deficiency is associated with transferrin saturation &le;20 percent and elevated ferritin level (typically between 100 to 800",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or even higher). However, percent transferrin saturation and serum ferritin levels above these levels (ie, 20 percent and 800",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      respectively) do not necessarily indicate that further iron supplementation would be without an erythropoietic stimulating effect. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Absolute and functional iron deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We target Hgb levels in the range of 10 to 11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in most CKD patients who are treated with ESAs. We do not target hemoglobin levels above 12",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link\">",
"       \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with anemia due to CKD and absolute iron deficiency (defined as a TSAT &le;20 percent and ferritin &le;100",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      we administer iron therapy. Among CKD patients in whom an increase in Hb concentration is desired and who have a TSAT &le;30 percent and ferritin &le;500",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      we also administer iron therapy. If iron therapy does not correct the hemoglobin concentration, ESA therapy may be indicated. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initiation of iron therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do not routinely administer intravenous iron to patients with ferritin levels above 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and anemia, although each patient should be individually assessed. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Initiation of iron therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among CKD patients who are receiving ESAs, we give maintenance iron therapy to prevent absolute iron deficiency (defined as TSAT &le;20 percent and ferritin &le;100",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"      Among CKD patients in whom an increase in hemoglobin concentration or decrease in ESA dose is desired, we administer iron therapy when the TSAT is &le;30 percent and ferritin &le;500",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      rather than withholding iron until the TSAT is &le;20 percent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for iron therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among non-dialysis CKD patients, we attempt initial therapy with oral iron rather than parenteral iron. Oral iron should be administered at a daily dose of at least 200 mg of elemental iron. Because of simplicity and cost issues, we suggest giving this as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37046?source=see_link\">",
"       ferrous sulfate",
"      </a>",
"      325 mg (65 mg elemental iron per tablet) three times daily. If the hemoglobin level is not achieved with modest doses of ESAs and the TSAT remains &le;30 percent, parenteral iron therapy should be administered, providing the serum ferritin level remains below 500",
"      <span class=\"nowrap\">",
"       ng/",
"      </span>",
"      mL and there is no evidence of active infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Indications for oral versus intravenous iron therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among home hemodialysis and peritoneal dialysis patients, we use intravenous iron therapy rather than oral iron. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Indications for oral versus intravenous iron therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If parenteral iron therapy is administered, we use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      in sucrose complex,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"       ferumoxytol",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      . The optimal regimens for either ferric gluconate in sucrose complex and iron sucrose are unclear. We administer these agents in the following regimens (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Iron sucrose and ferric gluconate in sucrose complex'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      300 to 400 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      can be administered once every week (or less often if necessary, ie for patient convenience, etc.) for two to three doses to provide a total dose of 600 to 1000 mg, as needed. If these are doses are not well tolerated, additional doses of 200 mg can often be used.",
"     </li>",
"     <li>",
"      250 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      in sucrose complex can be administered once weekly (or less often if necessary, ie for patient convenience, etc.) for three to four doses, as needed.",
"     </li>",
"     <li>",
"      510 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"       ferumoxytol",
"      </a>",
"      can be administered as a single dose via rapid intravenous infusion, repeated if needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We generally do not administer intravenous iron to patients with ferritin levels above 500",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      Occasionally patients will have ferritin concentrations above 500",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and still be anemic; among such patients, an initial trial of increased erythropoietin dose alone, without intravenous iron, may be considered if the hemoglobin level is persistently below 11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and the erythropoietin dose that is currently being used is not particularly high. Among patients who have a ferritin level above 500",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and do not achieve the target hemoglobin concentration with an increased erythropoietin dose, we judiciously give supplemental iron with or without a further increase in erythropoietin dose. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for iron therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/1\">",
"      Fern&aacute;ndez-Rodr&iacute;guez AM, Guindeo-Casas&uacute;s MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 1999; 34:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/2\">",
"      KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/3\">",
"      Dr&uuml;eke TB, B&aacute;r&aacute;ny P, Cazzola M, et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 1997; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/4\">",
"      NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. III. Iron support. Am J Kidney Dis 2001; 37(Suppl 1):S194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/5\">",
"      Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/6\">",
"      Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001; 16:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/7\">",
"      Charytan, C, Ounibi, W, Bailie, GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005; 11:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/8\">",
"      Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68:2846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/9\">",
"      Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/10\">",
"      Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012; 1:CD007857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/11\">",
"      Sloand JA, Shelly MA, Erenstone AL, et al. Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies. Perit Dial Int 1998; 18:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/12\">",
"      Prakash S, Walele A, Dimkovic N, et al. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int 2001; 21:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/13\">",
"      Li H, Wang SX. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int 2008; 28:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/14\">",
"      Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 1998; 9:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/15\">",
"      Johnson DW, Herzig KA, Gissane R, et al. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients. Nephrol Dial Transplant 2001; 16:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/16\">",
"      Johnson DW, Herzig KA, Gissane R, et al. Oral versus intravenous iron supplementation in peritoneal dialysis patients. Perit Dial Int 2001; 21 Suppl 3:S231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/17\">",
"      Bastani B, Islam S, Boroujerdi N. Iron absorption after single pharmacological oral iron loading test in patients on chronic peritoneal dialysis and in healthy volunteers. Perit Dial Int 2000; 20:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/18\">",
"      Dittrich E, Puttinger H, Schneider B, et al. Is absorption of high-dose oral iron sufficient in peritoneal dialysis patients? Perit Dial Int 2000; 20:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/19\">",
"      Nissenson AR, Berns JS, Sakiewicz P, et al. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 2003; 42:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/20\">",
"      Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/21\">",
"      Blaustein DA, Schwenk MH, Chattopadhyay J, et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int Suppl 2003; :S72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/22\">",
"      Bastani B, Jain A, Pandurangan G. Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure. Nephrology (Carlton) 2003; 8:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/23\">",
"      Danda RS, Kirk LJ, Pergola PE. High-dose iron gluconate in chronic kidney disease patients. Nephrology (Carlton) 2004; 9:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/24\">",
"      Jain AK, Bastani B. Safety profile of a high dose ferric gluconate in patients with severe chronic renal insufficiency. J Nephrol 2002; 15:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/25\">",
"      Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (&gt; or =250 mg) administration. Am J Kidney Dis 2003; 41:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/26\">",
"      Kosch M, Bahner U, Bettger H, et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/27\">",
"      Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005; 46:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/28\">",
"      Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/29\">",
"      Landry R, Jacobs PM, Davis R, et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005; 25:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/30\">",
"      Spinowitz BS, Schwenk MH, Jacobs PM, et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005; 68:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/31\">",
"      Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/32\">",
"      Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:386.",
"     </a>",
"    </li>",
"    <li>",
"     Feraheme prescribing information, June 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37752/abstract/34\">",
"      Grimmelt AC, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009; 71:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1943 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37752=[""].join("\n");
var outline_f36_55_37752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF IRON DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Absolute and functional iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS FOR IRON THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initiation of iron therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Maintenance iron therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATIONS FOR ORAL VERSUS INTRAVENOUS IRON THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ORAL IRON FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PARENTERAL IRON PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Iron dextran",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Iron sucrose and ferric gluconate in sucrose complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H443966\">",
"      Ferumoxytol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H444088\">",
"      - Efficacy and safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H444153\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28005?source=related_link\">",
"      Diagnosis of iron deficiency in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=related_link\">",
"      Iron sucrose: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3465?source=related_link\">",
"      Outcomes associated with nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_55_37753="Risk group stratification and prognosis for acute lymphoblastic leukemia in children";
var content_f36_55_37753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk group stratification and prognosis for acute lymphoblastic leukemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/55/37753/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37753/contributors\">",
"     Terzah M Horton, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37753/contributors\">",
"     C Philip Steuber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/55/37753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37753/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/55/37753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/55/37753/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/55/37753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute leukemia is the most common form of cancer in children, comprising approximately 30 percent of all childhood malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the acute leukemias, acute lymphoblastic leukemia (ALL) occurs five times more commonly than does acute myeloid leukemia (AML). Survival rates for ALL have improved dramatically since the 1980s, with a current five-year overall survival rate estimated at greater than 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This improvement in survival is due to treatment of a large number of children on sequential standardized research protocols. Approximately 75 to 80 percent of children with newly diagnosed ALL participate in such trials, the goals of which are to improve clinical outcomes while minimizing acute toxicities and late-occurring adverse events.",
"   </p>",
"   <p>",
"    The risk group stratification for acute-lymphoblastic leukemia in children will be reviewed here. The presentation, classification, treatment, and outcome of childhood ALL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current treatment protocols for ALL in children emphasize risk-based therapy in order to reduce toxicity in low-risk patients while ensuring appropriate, more aggressive therapy for those with a high risk of relapse. The development of such risk-based therapy regimens and the introduction of preventive central nervous system (CNS) therapy have helped to improve survival rates for children with ALL.",
"   </p>",
"   <p>",
"    Certain clinical and laboratory features have been historically correlated with prognosis (",
"    <a class=\"graphic graphic_table graphicRef71649 \" href=\"mobipreview.htm?0/35/574\">",
"     table 1",
"    </a>",
"    ). Features that continue to be used in risk stratification include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial WBC count",
"     </li>",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Cytogenetics and ploidy",
"     </li>",
"     <li>",
"      Immunologic subtype",
"     </li>",
"     <li>",
"      Rapidity of cytoreduction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As treatment regimens become more intense and successful, however, the association between the following features and outcome has become less or is no longer significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sex",
"     </li>",
"     <li>",
"      FAB morphology",
"     </li>",
"     <li>",
"      Mediastinal mass",
"     </li>",
"     <li>",
"      Organomegaly and lymphadenopathy",
"     </li>",
"     <li>",
"      Hemoglobin level",
"     </li>",
"     <li>",
"      Race",
"     </li>",
"     <li>",
"      Platelet count",
"     </li>",
"     <li>",
"      Serum immunoglobulins",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of acute lymphoid leukemia are usually first categorized by immunophenotyping and include the early B cell, mature B cell and T cell lineages. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Immunophenotype'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Early B cell lineage is the most common subgroup, and within this lineage, the following four risk groups with different outcomes have been identified based upon initial clinical and biological risk factors. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cytogenetics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-risk &mdash; Children with favorable age, low WBC count and favorable cytogenetic changes, such as hyperdiploidy, trisomies of 4, 10, and 17 or the presence of the ETV6-RUNX1 (formally TEL-AML1) fusion protein, are in the low-risk group and have the best prognosis, with reported four to five year, event-free survival (EFS) rates approaching 90 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cytogenetics'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Standard-risk &mdash; Patients with favorable age and low WBC count, but without favorable cytogenetic changes, are considered to have standard-risk ALL.",
"     </li>",
"     <li>",
"      High-risk &mdash; Patients older than 10 years of age, or those with unfavorable cytogenetic changes, are considered to have high-risk ALL.",
"     </li>",
"     <li>",
"      Very-high risk &mdash; Children in the very-high-risk group include those with cytogenetic markers of extreme hypodiploidy, t(9;22)",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      translocation (Philadelphia chromosome), t(4;11) MLL rearrangement, iAMP21 amplification",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      failure to achieve remission at the end of induction therapy. In the past, this group of patients had a poor prognosis, but many of these patients can be successfully treated with aggressive chemotherapy, often in combination with stem cell transplant. Patients older than 13 years of age are often also in this category (United States).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Support of risk stratification was illustrated in a retrospective review of 6238 children with ALL from the Children's Oncology Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/7\">",
"     7",
"    </a>",
"    ]. Risk stratification was based upon age, WBC count, sex, extramedullary disease, blast cytogenetics and ploidy, and early response to therapy (",
"    <a class=\"graphic graphic_table graphicRef71649 \" href=\"mobipreview.htm?0/35/574\">",
"     table 1",
"    </a>",
"    ). Four year, event-free survival rates based upon the risk groups above were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk &mdash; &gt;95 percent",
"     </li>",
"     <li>",
"      Standard risk &mdash; 90 to 95 percent",
"     </li>",
"     <li>",
"      High risk &mdash; 88 to 90 percent",
"     </li>",
"     <li>",
"      Very high risk &mdash; &lt;80 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WBC COUNT AND AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;WBC count and age at the time of diagnosis remain independent predictors of prognosis. They have been established by the National Cancer Institute (NCI) as the standard criteria for risk assignment at diagnosis in precursor B cell ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/9\">",
"     9",
"    </a>",
"    ], but are less predictive of outcome in T cell ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have demonstrated a linear relationship between initial WBC and outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Children with initial WBC",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL",
"    </span>",
"    have a more guarded prognosis and are stratified into a higher risk group (",
"    <a class=\"graphic graphic_table graphicRef71649 \" href=\"mobipreview.htm?0/35/574\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients older than 10 years, or younger than one year, also have less favorable outcomes and are assigned to higher risk groups (",
"    <a class=\"graphic graphic_table graphicRef71649 \" href=\"mobipreview.htm?0/35/574\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/12-17\">",
"     12-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infant ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infant ALL appears to have distinct biological characteristics. Most infants with ALL (60 to 80 percent) have translocations involving 11q23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. These translocations involve the MLL gene",
"    <span class=\"nowrap\">",
"     (myeloid/lymphoid,",
"    </span>",
"    or mixed-lineage, leukemia; also called ALL1 or HRX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. The cytogenetic rearrangements create a fusion protein within the",
"    <span class=\"nowrap\">",
"     MLL/ALL-1",
"    </span>",
"    gene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=see_link&amp;anchor=H5#H5\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\", section on '4;11 translocation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leukemias with MLL translocations have a characteristic, highly distinct gene expression profile, suggesting that they constitute a distinct disease, characterized by a high rate of early treatment failure and a very poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/19,20,24\">",
"     19,20,24",
"    </a>",
"    ], even when treated with more aggressive chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/25\">",
"     25",
"    </a>",
"    ]. Infants diagnosed within the first three months of life have a particularly guarded prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, the estimated three year event-free survival (EFS) rate in infants with ALL and an MLL rearrangement was 19 percent compared with 46 percent for patients with non-rearranged MLL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second series of 115 infants with ALL who were treated with a more aggressive regimen, estimated five year EFS was 34 versus 60 percent for those with or without MLL rearrangement, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants with ALL are typically treated with more aggressive chemotherapy regimens because they have poor responses to conventional therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/26,28-30\">",
"     26,28-30",
"    </a>",
"    ]. However, in one retrospective analysis of 106 infants with ALL, most (74 percent) responded to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    during the induction phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/31\">",
"     31",
"    </a>",
"    ]. These infants received conventional therapy and had better outcomes than did those who failed to respond to prednisone and received intensified therapy, with an estimated probability for EFS at 6 years of age of 53 versus 15 percent, respectively. A European retrospective analysis noted that 277 of 297 infants with ALL and an MLL rearrangement were able to attain a first complete remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/32\">",
"     32",
"    </a>",
"    ]. This study also suggested an improvement in disease-free survival with allogeneic hematopoietic cell transplantation in a subgroup of infants with a particularly poor prognosis. However, a similar study by the Children&rsquo;s Oncology Group (COG) was not able to duplicate these findings (in press).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CYTOGENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytogenetic features play an important role in the risk stratification in childhood ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/33\">",
"     33",
"    </a>",
"    ]. Abnormalities involving both chromosome number and chromosome structure, such as gene rearrangements and fusions (translocations), have an impact on prognosis. Cytogenic findings that affect risk-group stratification in current clinical trials from the United States include ETV6-RUNX1; trisomies of chromosomes 4, 10, and often 17; BCR-ABL; hypodiploidy, and the MLL translocation.",
"   </p>",
"   <p>",
"    This was illustrated in a study that analyzed cytogenetic data from 1725 children with B cell precursor ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/34\">",
"     34",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two chromosomal abnormalities, ETV6-RUNX1 (the t[12;21] translocation associated with a fusion protein formerly known as TEL-AML1) and high hyperdiploidy, were associated with a favorable outcome.",
"     </li>",
"     <li>",
"      Five abnormalities were associated with an increased risk of relapse. These included the following structural defects: iAMP21, the t(9;22) translocation associated with the BCR-ABL fusion protein (also known as the Philadelphia chromosome), MLL translocations, abnormal 17p, and loss of 13q.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Numeric abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerical abnormalities may involve the whole chromosome set (ploidy changes), or the gain or loss of individual chromosomes (aneuploidy changes). The following chromosomal numeric abnormalities are prognostic indicators in patients with ALL.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"High hyperdiploidy\" (50 or more chromosomes) is a favorable prognostic feature [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/5,35-38\">",
"       5,35-38",
"      </a>",
"      ]. High hyperdiploidy has been uniformly associated with good prognosis in ALL. Of patients with high hyperdiploidy, those with the best outcomes in clinical trials from the United States include those with either double trisomies of chromosomes 4 and 10, or triple trisomies of chromosomes 4, 10 and 17 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/39\">",
"       39",
"      </a>",
"      ]. Lower intensity therapy is frequently targeted in patients with triple trisomies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypodiploidy (fewer than 46 chromosomes) is a poor prognostic indicator. The likelihood of a poor outcome increases with a decrease in chromosomal numbers. Thus, hypodiploid cases lacking only a single chromosome have a similar prognosis to diploid cases, whereas cases, which are near-haploid (24 to 28 chromosomes), have the worst outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/35,40\">",
"       35,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although rare cases with near triploidy (68 to 80 chromosomes) or near tetraploidy (&gt;80 chromosomes) generally are associated with very poor outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/41\">",
"       41",
"      </a>",
"      ], a large series has reported favorable outcome in B-lineage cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Structural abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural gene abnormalities include translocations, deletions, insertions, and inversion. The following structural chromosomal abnormalities are prognostic indicators in patients with ALL.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The t(12;21) translocation creates the TEL-AML1 fusion gene (also known as ETV6-RUNX1). This structural change is associated with a favorable prognosis, and patients with this finding are assigned to low-risk treatment. Late relapses are more common in this group, but these patients have an excellent response rate to chemotherapy following relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The t(9;22) translocation (also referred to as the Philadelphia chromosome) is one of two structural rearrangements associated with poor prognosis (the other is MLL gene rearrangement, which is discussed below). t(9;22) translocation is found in 4 percent of ALL cases and can be seen with either B cell or T cell ALL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/44\">",
"       44",
"      </a>",
"      ]. Because of its association with poor outcome, patients with this abnormality are assigned to higher intensity treatment, including the use of a tyrosine kinase inhibitor.",
"      <br/>",
"      <br/>",
"      This translocation creates the BCR-ABL fusion protein, which encodes a dysfunctional tyrosine kinase. The tyrosine kinase inhibitor imatinib mesylate has been used successfully to treat chronic myeloid leukemia (CML) in adults, a disease that is linked to the presence of the Philadelphia chromosome. Although imatinib induces an initial response in many adults with ALL and the t(9:22) translocation, some patients develop drug resistance and relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H19#H19\">",
"       \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Philadelphia chromosome positive ALL'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rearrangements involving the MLL gene at 11q23 are associated with a poor prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/46\">",
"       46",
"      </a>",
"      ]. Patients with these lesions often have elevated FLT3 expression and have been treated with FLT3 inhibitors such as lestaurtinib [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/47\">",
"       47",
"      </a>",
"      ], although the efficacy of FLT3 inhibitors as standard of care has yet to be established.",
"     </li>",
"     <li>",
"      Although the t(1;19) translocation associated with the E2A-PBX1 fusion product was initially identified as a poor prognostic feature, it does not appear to have prognostic significance based upon data from clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genome-wide association study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genome-wide association studies have shown the predictive value of using gene expression profiling based upon the chromosomal abnormalities on ALL prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Studies using germline single-nucleotide polymorphisms (SNPs) have shown that several SNPs have been associated with minimal residual disease at the end of induction therapy, increased likelihood of relapse, altered antileukemic drug pharmokinetics, and immunophenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results demonstrate the inherited genetic variation to therapy in childhood ALL. Future studies will be needed to determine whether genomic profiling will aid in ALL risk assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IMMUNOPHENOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precursor T cell ALL and mature B cell ALL have historically been associated with poor prognosis. Patients with these types of ALL are treated according to different protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     T cell ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the outcomes in T cell ALL are directly related to immunophenotype or due to the increased incidence of elevated initial WBC counts and occurrence in older patients is not clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. Nonetheless, patients with T cell ALL are often treated differently than patients with standard risk Precursor B cell ALL; specific approaches vary according to the treatment center. Some centers treat T cell ALL with intensive, shorter (one year) chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/60\">",
"     60",
"    </a>",
"    ]. Other institutions treat T cell ALL as high-risk ALL (",
"    <a class=\"graphic graphic_table graphicRef71649 \" href=\"mobipreview.htm?0/35/574\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/59\">",
"     59",
"    </a>",
"    ]. Younger patients with the T cell immunophenotype who do not have high WBC counts or bulky disease have done well with either T cell specific or higher-risk ALL treatment protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/58,60,61\">",
"     58,60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a series of 125 children with T cell ALL who were treated the same as high-risk Precursor B cell ALL, there were no significant differences based on age, presenting WBC count, sex, CNS involvement, or presence of a mediastinal mass, which could prospectively identify those children with T cell ALL who experienced either induction failure or early relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/59\">",
"     59",
"    </a>",
"    ]. Gene expression profiling holds promise for being able to prospectively detect patients with T cell ALL at risk for induction failure, relapse,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shortened overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/62-64\">",
"     62-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mature B cell ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mature B cell ALL has a different biology and a poorer prognosis than does precursor B ALL. Almost all cases of mature B cell ALL demonstrate FAB L3 morphology and are associated with the t(8;14) translocation. The similarity between the molecular mechanisms associated with these translocations and those that occur in Burkitt's lymphoma supports the hypothesis that mature B cell ALL represents a disseminated form of Burkitt's lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\", section on 'Classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mature B cell ALL respond poorly to conventional ALL treatment but have a better response to therapy designed for Burkitt's lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/65\">",
"     65",
"    </a>",
"    ]. This therapy includes several courses of intensive therapy with a large number of chemotherapeutic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=see_link\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link&amp;anchor=H22#H22\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Burkitt-type ALL-L3'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RATE OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important prognostic factors in ALL is initial response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/5,67-69\">",
"     5,67-69",
"    </a>",
"    ]. In one controlled trial, 2090 children with ALL were randomly assigned, independent of risk factors, to receive either standard or intensified therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/5\">",
"     5",
"    </a>",
"    ]. In multivariate analysis, after controlling for age, sex, and presenting WBC count, the bone marrow blast percentage on day eight of induction therapy, remission status at the end of induction therapy, and blast karyotype were the only significant predictors of outcome. The effects of these risk factors were similar in both groups. Other studies support early response to therapy (eg, day 8 in peripheral blood minimal residual disease) as an independent prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/67-72\">",
"     67-72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MINIMAL RESIDUAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although response rate is an important factor in predicting prognosis, improved methods of assessing treatment response are desirable. Most bone marrow aspirates performed at the end of induction therapy show histologic evidence of \"complete\" remission (CR), defined as less than 5 percent lymphoblasts in a bone marrow with evidence of hematopoietic recovery.",
"   </p>",
"   <p>",
"    Many patients in clinical CR, however, continue to have small numbers of leukemic lymphoblasts in their bone marrow. The presence of such \"minimal residual disease\" (MRD) can be detected by flow cytometry or polymerase chain reaction at various points in the treatment course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. A detailed discussion of this issue is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31625?source=see_link\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large, prospective MRD monitoring studies in pediatric ALL confirm that the probability of long-term, relapse-free survival is directly related to the level of residual disease, both early in the course of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/70,77-81\">",
"     70,77-81",
"    </a>",
"    ] and at later time points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/79,82,83\">",
"     79,82,83",
"    </a>",
"    ]. In a semi-quantitative MRD study of 246 children with ALL, multivariate analysis indicated that PCR detection of &gt;10",
"    <sup>",
"     -2",
"    </sup>",
"    residual blasts (ie, more than one leukemic cell per 100 nucleated cells) after intensive induction chemotherapy was the most powerful independent predictor of early relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When later time points were analyzed, a MRD burden of &gt;10",
"    <sup>",
"     -3",
"    </sup>",
"    (ie, more than one leukemic cell per 1000 nucleated cells) was associated with significantly higher relapse rates. Other studies have confirmed the significance of serial, quantitative measurements of residual disease, indicating that the timing of disappearance and reappearance of marrow blasts is crucial in predicting relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/79,84\">",
"     79,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The European pediatric cooperative group, I-BFM-SG, and the Children's Oncology Group (COG) have begun prospective trials in which results of a semiquantitative MRD assay are used to stratify postremission treatment in childhood ALL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31625?source=see_link\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DRUG METABOLISM AND RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro resistance of the malignant cells to commonly employed agents (eg, glucocorticoids,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/17/41240?source=see_link\">",
"     etoposide",
"    </a>",
"    , L-asparaginase,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/19/31029?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) has been shown to be an independent adverse prognostic factor in children with low-risk ALL who are treated on a number of protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. Ongoing studies, such as the use of gene expression profiling techniques, are engaged in methods for documenting the mechanisms underlying this resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/88-98\">",
"     88-98",
"    </a>",
"    ] and adapting treatment based on these patients' drug resistance profile. There is also evidence that genetic polymorphisms of drug metabolism enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/94,99-103\">",
"     94,99-103",
"    </a>",
"    ], as well as the switch from",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/55/37753/abstract/104,105\">",
"     104,105",
"    </a>",
"    ], might influence response to therapy in some children with ALL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Important risk stratification criteria for acute lymphoblastic leukemia (ALL) in children include white blood cell (WBC) count, age at the time of diagnosis, cytogenetics, immunophenotype, and response to induction therapy (",
"      <a class=\"graphic graphic_table graphicRef71649 \" href=\"mobipreview.htm?0/35/574\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with initial WBC",
"      <span class=\"nowrap\">",
"       &gt;50,000/microL",
"      </span>",
"      are assigned to the high risk group. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'WBC count and age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children older than 10 years are assigned to the high risk group. Those younger than one year and those older than 13 years (in the United States) are assigned to the very high risk group. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'WBC count and age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytogenic characteristics of ALL lymphoblasts affect risk stratification as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lesser risk &mdash; Hyperdiploid (50 to 67 chromosomes) (Europe), trisomies 4 or 10, and translocation (12;21) encoding the ETV-RUNX1 protein (United States)",
"     </li>",
"     <li>",
"      Very high risk &mdash; Translocations (9;22) and (4;11) or the iAMP21 amplification, and hypodiploid (&lt;45 chromosomes) (Europe) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Cytogenetics'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precursor T cell ALL and mature B cell ALL are associated with poorer prognosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prognosis is directly related to the level of residual disease following induction chemotherapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Minimal residual disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER Cancer Statistic Review, 1973-1999. National Cancer Institute, Bethesda, MD, 2000. p.467.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/2\">",
"      Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/3\">",
"      Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/4\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/5\">",
"      Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001; 113:103.",
"     </a>",
"    </li>",
"    <li>",
"     Margolin JF, Steuber CP, Poplack DG. Acute lymphoblastic leukemia. In: Principles and Practice of Pediatric Oncology, 4th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. p.489.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/7\">",
"      Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007; 109:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/8\">",
"      Moorman AV, Richards SM, Martineau M, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood 2003; 102:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/9\">",
"      Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/10\">",
"      Maloney KW, Shuster JJ, Murphy S, et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000; 14:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/11\">",
"      Simone JV, Verzosa MS, Rudy JA. Initial features and prognosis in 363 children with acute lymphocytic leukemia. Cancer 1975; 36:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/12\">",
"      Sather HN. Age at diagnosis in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1986; 14:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/13\">",
"      Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/14\">",
"      Reaman G, Zeltzer P, Bleyer WA, et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol 1985; 3:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/15\">",
"      Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/16\">",
"      Chessells JM, Eden OB, Bailey CC, et al. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1994; 8:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/17\">",
"      Crist W, Pullen J, Boyett J, et al. Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis--a Pediatric Oncology Group Study. J Clin Oncol 1988; 6:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/18\">",
"      Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/19\">",
"      Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994; 84:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/20\">",
"      Hilden JM, Frestedt JL, Moore RO, et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). Blood 1995; 86:3876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/21\">",
"      Cimino G, Lo Coco F, Biondi A, et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood 1993; 82:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/22\">",
"      Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/23\">",
"      Djabali M, Selleri L, Parry P, et al. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 1992; 2:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/24\">",
"      Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/25\">",
"      Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/26\">",
"      Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006; 108:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/27\">",
"      Kang H, Wilson CS, Harvey RC, et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012; 119:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/28\">",
"      Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003; 101:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/29\">",
"      Stam RW, den Boer ML, Pieters R. Towards targeted therapy for infant acute lymphoblastic leukaemia. Br J Haematol 2006; 132:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/30\">",
"      Nagayama J, Tomizawa D, Koh K, et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood 2006; 107:4663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/31\">",
"      D&ouml;rdelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/32\">",
"      Mann G, Attarbaschi A, Schrappe M, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010; 116:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/33\">",
"      Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009; 144:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/34\">",
"      Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/35\">",
"      Heerema NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (&gt; 50 chromosomes). J Clin Oncol 2000; 18:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/36\">",
"      Chauvenet AR, Martin PL, Devidas M, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood 2007; 110:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/37\">",
"      Rubnitz JE, Wichlan D, Devidas M, et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2008; 26:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/38\">",
"      Dastugue N, Suciu S, Plat G, et al. Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood 2013; 121:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/39\">",
"      Sutcliffe MJ, Shuster JJ, Sather HN, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. Leukemia 2005; 19:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/40\">",
"      Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/41\">",
"      Pui CH, Carroll AJ, Head D, et al. Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood. Blood 1990; 76:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/42\">",
"      Raimondi SC, Zhou Y, Shurtleff SA, et al. Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. Cancer Genet Cytogenet 2006; 169:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/43\">",
"      Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/44\">",
"      Jones LK, Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 2005; 130:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/45\">",
"      Uckun FM, Nachman JB, Sather HN, et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer 1998; 83:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/46\">",
"      Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/47\">",
"      Brown P, Levis M, Shurtleff S, et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/48\">",
"      Uckun FM, Sensel MG, Sather HN, et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1998; 16:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/49\">",
"      Bhojwani D, Kang H, Menezes RX, et al. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol 2008; 26:4376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/50\">",
"      Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/51\">",
"      Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/52\">",
"      Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/53\">",
"      Trevi&ntilde;o LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 2009; 41:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/54\">",
"      Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 2009; 41:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/55\">",
"      Greaves MF, Janossy G, Peto J, Kay H. Immunologically defined subclasses of acute lymphoblastic leukaemia in children: their relationship to presentation features and prognosis. Br J Haematol 1981; 48:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/56\">",
"      Kalwinsky DK, Roberson P, Dahl G, et al. Clinical relevance of lymphoblast biological features in children with acute lymphoblastic leukemia. J Clin Oncol 1985; 3:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/57\">",
"      Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/58\">",
"      Shuster JJ, Falletta JM, Pullen DJ, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 75:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/59\">",
"      Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21:3616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/60\">",
"      Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998; 82:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/61\">",
"      van den Berg H, Zsiros J, Veneberg A, et al. Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia. Med Pediatr Oncol 1998; 30:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/62\">",
"      Gottardo NG, Hoffmann K, Beesley AH, et al. Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol 2007; 137:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/63\">",
"      Winter SS, Jiang Z, Khawaja HM, et al. Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2007; 110:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/64\">",
"      Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/65\">",
"      Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009; 113:6330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/66\">",
"      Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-M&uuml;nster Group. J Clin Oncol 1995; 13:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/67\">",
"      Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002; 87:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/68\">",
"      Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-M&uuml;nster. Leukemia 2000; 14:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/69\">",
"      Visser JH, Wessels G, Hesseling PB, et al. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001; 18:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/70\">",
"      Laughton SJ, Ashton LJ, Kwan E, et al. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/71\">",
"      Roy A, Bradburn M, Moorman AV, et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005; 129:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/72\">",
"      Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27:5168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/73\">",
"      Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/74\">",
"      Gameiro P, Moreira I, Yetgin S, et al. Polymerase chain reaction (PCR)- and reverse transcription PCR-based minimal residual disease detection in long-term follow-up of childhood acute lymphoblastic leukaemia. Br J Haematol 2002; 119:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/75\">",
"      Marshall GM, Haber M, Kwan E, et al. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/76\">",
"      Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia 2003; 17:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/77\">",
"      van Dongen JJ, Seriu T, Panzer-Gr&uuml;mayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/78\">",
"      Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/79\">",
"      Cav&eacute; H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/80\">",
"      Nyvold C, Madsen HO, Ryder LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/81\">",
"      Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/82\">",
"      Goulden N, Bader P, Van Der Velden V, et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/83\">",
"      Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008; 111:5477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/84\">",
"      Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99:4386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/85\">",
"      Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21:3262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/86\">",
"      Steinbach D, Wittig S, Cario G, et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 2003; 102:4493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/87\">",
"      Frost BM, Forestier E, Gustafsson G, et al. Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood 2004; 104:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/88\">",
"      Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004; 351:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/89\">",
"      Cario G, Stanulla M, Fine BM, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005; 105:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/90\">",
"      Fine BM, Kaspers GJ, Ho M, et al. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005; 65:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/91\">",
"      Bachmann PS, Gorman R, Mackenzie KL, et al. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 2005; 105:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/92\">",
"      Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105:4752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/93\">",
"      Beesley AH, Cummings AJ, Freitas JR, et al. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol 2005; 131:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/94\">",
"      Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/95\">",
"      Flotho C, Coustan-Smith E, Pei D, et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006; 108:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/96\">",
"      Iwamoto S, Mihara K, Downing JR, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007; 117:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/97\">",
"      Choi S, Henderson MJ, Kwan E, et al. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood 2007; 110:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/98\">",
"      Estes DA, Lovato DM, Khawaja HM, et al. Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol 2007; 139:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/99\">",
"      Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005; 293:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/100\">",
"      de Jonge R, Hooijberg JH, van Zelst BD, et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 2005; 106:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/101\">",
"      Ge Y, Haska CL, LaFiura K, et al. Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Clin Cancer Res 2007; 13:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/102\">",
"      Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109:4151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/103\">",
"      Koppen IJ, Hermans FJ, Kaspers GJ. Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. Br J Haematol 2010; 148:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/104\">",
"      Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005; 129:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/55/37753/abstract/105\">",
"      Igarashi S, Manabe A, Ohara A, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 2005; 23:6489.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6248 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37753=[""].join("\n");
var outline_f36_55_37753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WBC COUNT AND AGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infant ALL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CYTOGENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Numeric abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Structural abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genome-wide association study",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IMMUNOPHENOTYPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      T cell ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mature B cell ALL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RATE OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MINIMAL RESIDUAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DRUG METABOLISM AND RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6248\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6248|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/35/574\" title=\"table 1\">",
"      Risk assignment childhood ALL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31625?source=related_link\">",
"      Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=related_link\">",
"      Detection of minimal residual disease in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_55_37754="12-lead ECG ventricular tachycardia in ARVC";
var content_f36_55_37754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1184px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) showing ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy (ARVC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ventricular tachycardia in arrhythmogenic right venricular cardiomyopathy (ARVC) usually arises from the free wall of the right ventricle, resulting in a left bundle branch morphology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Podrid, PJ, Kowey, PR (Eds), Cardiac Arrhythmia - Mechanisms, Diagnosis, and Management, Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37754=[""].join("\n");
var outline_f36_55_37754=null;
var title_f36_55_37755="Male infertility no treatment";
var content_f36_55_37755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of male factor infertility for which medical treatment of the male for infertility is not available",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Etiology",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Klinefelter syndrome or variants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Y chromosome microdeletions (azoospermia and hyalinized tubules)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sertoli cell only syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Germ cell arrest at primary spermatocyte or earlier stage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other - idiopathic, cryptorchidism, post-irradiation or post-chemotherapy (azoospermia associated with hyalinized tubules or Sertoli cells only)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            General aspects of treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Testosterone replacement if serum testosterone low or serum LH elevated; this regimen will improve symptoms of hypogonadism but will not restore fertility",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retrieval of spermatozoa or spermatids from testicular biopsy followed by intracytoplasmic sperm injection; injection of spermatocytes has not resulted in viable embryos in humans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Possible germ cell transplantation (ethical and social problems)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37755=[""].join("\n");
var outline_f36_55_37755=null;
var title_f36_55_37756="Classification PN tumors";
var content_f36_55_37756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of peripheral nerve tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Non-neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ganglion cyst, mucous cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heterotopic ossification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoid granuloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leprosy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Palisaded encapsulated neuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucosal neuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Localized hypertrophic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipofibromatous hamartoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuromuscular choristoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desmoid tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Nerve sheath neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cutaneous neurofibroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intraneural neurofibroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plexiform neurofibroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Schwannoma (aka neurilemmoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cellular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Melanotic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Psammomatous melanotic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ancient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Plexiform",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schwannomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perineurioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nerve sheath myxoma (previously aka myxoid neurothekeoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cellular and mixed-type neurothekeoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ganglioneuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemangioblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Tumors of peripheral nerve sheath origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant peripheral nerve sheath tumor (aka neurogenic sarcoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant Triton tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Tumors of non-peripheral nerve sheath origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurolymphomatosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John E Donahue, MD and James M Gilchrist, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37756=[""].join("\n");
var outline_f36_55_37756=null;
var title_f36_55_37757="Diagnostic evaluation ILD";
var content_f36_55_37757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic studies in suspected interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            To assess extent and severity of disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Radiographic studies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chest radiographs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            High-resolution computed tomography",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ventilation perfusion scan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other studies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Electrocardiogram",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Echocardiogram",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Pulmonary function studies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Spirometry",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pulse oximetry and arterial blood gases (resting, sleeping, and with exercise)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Six-minute walk",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diffusion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pressure-volume curve",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infant studies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            To identify primary disorders that predispose to interstitial lung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Immune studies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            HIV ELISA",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Immunoglobulins including IgE",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Skin tests for delayed hypersensitivity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Response to immunizations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            T and B cell subsets",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Complement",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Others as indicated",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other studies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Barium swallow",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            pH probe",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\" colspan=\"2\">",
"            To identify primary interstitial lung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2\">",
"            Test",
"           </td>",
"           <td class=\"subtitle2\">",
"            Potential diagnosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\">",
"            Noninvasive studies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Antinuclear antibody",
"           </td>",
"           <td>",
"            Autoimmune disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Angiotensin converting enzyme",
"           </td>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Antineutrophil cytoplasmic antibody",
"           </td>",
"           <td>",
"            Vasculitic syndromes, including granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anti-glomerular basement membrane antibody",
"           </td>",
"           <td>",
"            Pulmonary anti-glomerular basement membrane disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypersensitivity screen",
"           </td>",
"           <td>",
"            Hypersensitivity syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infectious disease evaluation: cultures, titers, skin tests",
"           </td>",
"           <td>",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Genetic studies for surfactant dysfunction",
"           </td>",
"           <td>",
"            Surfactant dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Serum and urine amino acids",
"           </td>",
"           <td>",
"            Lipid storage disorders and other inborn errors of metabolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\">",
"            Invasive studies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cardiac catheterization (in selected cases)",
"           </td>",
"           <td>",
"            Congestive heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bronchoalveolar lavage",
"           </td>",
"           <td>",
"            Infection, aspiration, hemorrhage, pulmonary alveolar proteinosis, lysosomal storage disorders, Langerhans cell histiocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Transbronchial biopsy",
"           </td>",
"           <td>",
"            Infection, rejection post-lung transplant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Transthoracic lung biopsy",
"           </td>",
"           <td>",
"            Idiopathic interstitial pneumonitis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus; ELISA: enzyme-linked immunosorbent assay.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Fan LL, Deterding RR, Langston C. Pediatric interstitial lung disease revisited. Pediatr Pulmonol 2004; 38:369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37757=[""].join("\n");
var outline_f36_55_37757=null;
var title_f36_55_37758="Prevalence of Down syndrome by maternal age";
var content_f36_55_37758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Estimated prevalence of births with Down syndrome (95% CI) in the absence of antenatal screening in England and Wales 1990-1998: comparison of logit logistic curve with exponential curve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 395px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Morris, JK, Mutton, DE, Alberman, E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002; 9:2. Copyright &copy;2002 The Royal Society of Medicine Press, London.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37758=[""].join("\n");
var outline_f36_55_37758=null;
var title_f36_55_37759="Enteric duplication cyst";
var content_f36_55_37759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enteric duplication cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance image of an enteric duplication cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_55_37759=[""].join("\n");
var outline_f36_55_37759=null;
